Some of the potential benefits of the HemoStream(TM) catheter include:
- Patented Triple Arterial Lumen Design: Ensures functional flow rates
in the event that two lumens become completely occluded.
- Transition: Provides atraumatic over-the-wire insertion without the
need for a peel-away sheath.
- 360 degree Arterial Tip Configuration: Eliminates catheter "side-
walling" against vessel.
In April 2007, Angiotech entered into an agreement with Rex Medical, LP, which granted Angiotech an exclusive license to market and distribute the HemoStream(TM) catheter worldwide. The U.S. Food and Drug Administration (FDA) has given clearance to begin marketing the HemoStream(TM) chronic dialysis catheter in the United States.
Angiotech will be exhibiting in Booth #233 at the 33rd Annual Meeting
of the Society of Interventional Radiologists to be held March 15-18th,
2008 in Washington, D.C. More information about the meeting can be found on
the Society of Interventional Radiology website at:
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical
and medical device company with over 1,600 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases
or complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech (NASDAQ:
ANPI, TSX: ANP), please visit http://w
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved